Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.
Identifieur interne : 002F98 ( PubMed/Corpus ); précédent : 002F97; suivant : 002F99Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.
Auteurs : Janaki Amin ; Mark A. Boyd ; Nagalingeswaran Kumarasamy ; Cecilia L. Moore ; Marcello H. Losso ; Chidi A. Nwizu ; Lerato Mohapi ; Stephen J. Kerr ; Annette H. Sohn ; Hedy Teppler ; Boris Renjifo ; Jean-Michel Molina ; Sean Emery ; David A. CooperSource :
- PloS one [ 1932-6203 ] ; 2015.
English descriptors
- KwdEn :
- Adult, Drug Therapy, Combination, HIV Infections (drug therapy), HIV Integrase Inhibitors (administration & dosage), HIV Integrase Inhibitors (adverse effects), HIV Integrase Inhibitors (therapeutic use), HIV Protease Inhibitors (administration & dosage), HIV Protease Inhibitors (adverse effects), HIV Protease Inhibitors (therapeutic use), HIV-1, Humans, Lopinavir (administration & dosage), Lopinavir (adverse effects), Lopinavir (therapeutic use), Male, Raltegravir Potassium (administration & dosage), Raltegravir Potassium (adverse effects), Raltegravir Potassium (therapeutic use), Ritonavir (administration & dosage), Ritonavir (adverse effects), Ritonavir (therapeutic use), Secondary Care.
- MESH :
- chemical , administration & dosage : HIV Integrase Inhibitors, HIV Protease Inhibitors, Lopinavir, Raltegravir Potassium, Ritonavir.
- chemical , adverse effects : HIV Integrase Inhibitors, HIV Protease Inhibitors, Lopinavir, Raltegravir Potassium, Ritonavir.
- drug therapy : HIV Infections.
- chemical , therapeutic use : HIV Integrase Inhibitors, HIV Protease Inhibitors, Lopinavir, Raltegravir Potassium, Ritonavir.
- Adult, Drug Therapy, Combination, HIV-1, Humans, Male, Secondary Care.
Abstract
To determine the durability over 96 weeks of safety and efficacy of lopinavir/ritonavir (LPV/r) and raltegravir (RAL) which was demonstrated to have non-inferior efficacy relative to a regimen of LPV/r with nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) (Control) in primary analysis at 48 weeks.
DOI: 10.1371/journal.pone.0118228
PubMed: 25723472
Links to Exploration step
pubmed:25723472Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.</title><author><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Kumarasamy, Nagalingeswaran" sort="Kumarasamy, Nagalingeswaran" uniqKey="Kumarasamy N" first="Nagalingeswaran" last="Kumarasamy">Nagalingeswaran Kumarasamy</name><affiliation><nlm:affiliation>Y. R. Gaitonde Centre for AIDS Research and Education, Chennai, India.</nlm:affiliation></affiliation></author><author><name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L" last="Moore">Cecilia L. Moore</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Losso, Marcello H" sort="Losso, Marcello H" uniqKey="Losso M" first="Marcello H" last="Losso">Marcello H. Losso</name><affiliation><nlm:affiliation>Hospital JM Ramos Mejia, Buenos Aires, Argentina.</nlm:affiliation></affiliation></author><author><name sortKey="Nwizu, Chidi A" sort="Nwizu, Chidi A" uniqKey="Nwizu C" first="Chidi A" last="Nwizu">Chidi A. Nwizu</name><affiliation><nlm:affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Mohapi, Lerato" sort="Mohapi, Lerato" uniqKey="Mohapi L" first="Lerato" last="Mohapi">Lerato Mohapi</name><affiliation><nlm:affiliation>University of the Witwatersrand and Baragwanath Hospital, Johannesburg, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Kerr, Stephen J" sort="Kerr, Stephen J" uniqKey="Kerr S" first="Stephen J" last="Kerr">Stephen J. Kerr</name><affiliation><nlm:affiliation>UNSW Australia, The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand.</nlm:affiliation></affiliation></author><author><name sortKey="Sohn, Annette H" sort="Sohn, Annette H" uniqKey="Sohn A" first="Annette H" last="Sohn">Annette H. Sohn</name><affiliation><nlm:affiliation>TREAT Asia, amfAR, The Foundation for AIDS Research, Bangkok, Thailand.</nlm:affiliation></affiliation></author><author><name sortKey="Teppler, Hedy" sort="Teppler, Hedy" uniqKey="Teppler H" first="Hedy" last="Teppler">Hedy Teppler</name><affiliation><nlm:affiliation>Merck Research Laboratories, Merck Sharp & Dohme, Whitehouse Station, New Jersey, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Renjifo, Boris" sort="Renjifo, Boris" uniqKey="Renjifo B" first="Boris" last="Renjifo">Boris Renjifo</name><affiliation><nlm:affiliation>Global Medical Affairs Virology, Abbvie, North Chicago, Illinois, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name><affiliation><nlm:affiliation>Service des Maladies Infectieuses, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25723472</idno><idno type="pmid">25723472</idno><idno type="doi">10.1371/journal.pone.0118228</idno><idno type="wicri:Area/PubMed/Corpus">002F98</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002F98</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.</title><author><name sortKey="Amin, Janaki" sort="Amin, Janaki" uniqKey="Amin J" first="Janaki" last="Amin">Janaki Amin</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Boyd, Mark A" sort="Boyd, Mark A" uniqKey="Boyd M" first="Mark A" last="Boyd">Mark A. Boyd</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Kumarasamy, Nagalingeswaran" sort="Kumarasamy, Nagalingeswaran" uniqKey="Kumarasamy N" first="Nagalingeswaran" last="Kumarasamy">Nagalingeswaran Kumarasamy</name><affiliation><nlm:affiliation>Y. R. Gaitonde Centre for AIDS Research and Education, Chennai, India.</nlm:affiliation></affiliation></author><author><name sortKey="Moore, Cecilia L" sort="Moore, Cecilia L" uniqKey="Moore C" first="Cecilia L" last="Moore">Cecilia L. Moore</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Losso, Marcello H" sort="Losso, Marcello H" uniqKey="Losso M" first="Marcello H" last="Losso">Marcello H. Losso</name><affiliation><nlm:affiliation>Hospital JM Ramos Mejia, Buenos Aires, Argentina.</nlm:affiliation></affiliation></author><author><name sortKey="Nwizu, Chidi A" sort="Nwizu, Chidi A" uniqKey="Nwizu C" first="Chidi A" last="Nwizu">Chidi A. Nwizu</name><affiliation><nlm:affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Mohapi, Lerato" sort="Mohapi, Lerato" uniqKey="Mohapi L" first="Lerato" last="Mohapi">Lerato Mohapi</name><affiliation><nlm:affiliation>University of the Witwatersrand and Baragwanath Hospital, Johannesburg, South Africa.</nlm:affiliation></affiliation></author><author><name sortKey="Kerr, Stephen J" sort="Kerr, Stephen J" uniqKey="Kerr S" first="Stephen J" last="Kerr">Stephen J. Kerr</name><affiliation><nlm:affiliation>UNSW Australia, The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand.</nlm:affiliation></affiliation></author><author><name sortKey="Sohn, Annette H" sort="Sohn, Annette H" uniqKey="Sohn A" first="Annette H" last="Sohn">Annette H. Sohn</name><affiliation><nlm:affiliation>TREAT Asia, amfAR, The Foundation for AIDS Research, Bangkok, Thailand.</nlm:affiliation></affiliation></author><author><name sortKey="Teppler, Hedy" sort="Teppler, Hedy" uniqKey="Teppler H" first="Hedy" last="Teppler">Hedy Teppler</name><affiliation><nlm:affiliation>Merck Research Laboratories, Merck Sharp & Dohme, Whitehouse Station, New Jersey, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Renjifo, Boris" sort="Renjifo, Boris" uniqKey="Renjifo B" first="Boris" last="Renjifo">Boris Renjifo</name><affiliation><nlm:affiliation>Global Medical Affairs Virology, Abbvie, North Chicago, Illinois, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Molina, Jean Michel" sort="Molina, Jean Michel" uniqKey="Molina J" first="Jean-Michel" last="Molina">Jean-Michel Molina</name><affiliation><nlm:affiliation>Service des Maladies Infectieuses, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Emery, Sean" sort="Emery, Sean" uniqKey="Emery S" first="Sean" last="Emery">Sean Emery</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name><affiliation><nlm:affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Drug Therapy, Combination</term><term>HIV Infections (drug therapy)</term><term>HIV Integrase Inhibitors (administration & dosage)</term><term>HIV Integrase Inhibitors (adverse effects)</term><term>HIV Integrase Inhibitors (therapeutic use)</term><term>HIV Protease Inhibitors (administration & dosage)</term><term>HIV Protease Inhibitors (adverse effects)</term><term>HIV Protease Inhibitors (therapeutic use)</term><term>HIV-1</term><term>Humans</term><term>Lopinavir (administration & dosage)</term><term>Lopinavir (adverse effects)</term><term>Lopinavir (therapeutic use)</term><term>Male</term><term>Raltegravir Potassium (administration & dosage)</term><term>Raltegravir Potassium (adverse effects)</term><term>Raltegravir Potassium (therapeutic use)</term><term>Ritonavir (administration & dosage)</term><term>Ritonavir (adverse effects)</term><term>Ritonavir (therapeutic use)</term><term>Secondary Care</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>HIV Integrase Inhibitors</term><term>HIV Protease Inhibitors</term><term>Lopinavir</term><term>Raltegravir Potassium</term><term>Ritonavir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>HIV Integrase Inhibitors</term><term>HIV Protease Inhibitors</term><term>Lopinavir</term><term>Raltegravir Potassium</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>HIV Integrase Inhibitors</term><term>HIV Protease Inhibitors</term><term>Lopinavir</term><term>Raltegravir Potassium</term><term>Ritonavir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Drug Therapy, Combination</term><term>HIV-1</term><term>Humans</term><term>Male</term><term>Secondary Care</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To determine the durability over 96 weeks of safety and efficacy of lopinavir/ritonavir (LPV/r) and raltegravir (RAL) which was demonstrated to have non-inferior efficacy relative to a regimen of LPV/r with nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) (Control) in primary analysis at 48 weeks.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25723472</PMID><DateCreated><Year>2015</Year><Month>02</Month><Day>28</Day></DateCreated><DateCompleted><Year>2016</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2015</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.</ArticleTitle><Pagination><MedlinePgn>e0118228</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0118228</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the durability over 96 weeks of safety and efficacy of lopinavir/ritonavir (LPV/r) and raltegravir (RAL) which was demonstrated to have non-inferior efficacy relative to a regimen of LPV/r with nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) (Control) in primary analysis at 48 weeks.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Open label, centrally randomised trial.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Recruitment was from 37 primary and secondary care sites from Africa, Asia, Australia, Europe and Latin America.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">541 HIV-1 infected adults virologically failing first-line non-NRTI + 2N(t)RTI, with no previous exposure to protease inhibitors or integrase strand transfer inhibitors were analysed, 425 completed 96 weeks follow up on randomised therapy.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Randomisation was 1:1 to Control or RAL.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Differences between the proportion of participants with plasma HIV-1 RNA (VL) <200 copies/mL by intention to treat were compared with a non-inferiority margin of -12%. Differences in biochemical, haematological and metabolic changes were assessed using T-tests.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">VL <200 copies/mL at 96 weeks was: RAL 80.4%, Control 76.0% (difference: 4.4 [95%CI -2.6, 11.3]) and met non-inferiority criteria. The RAL arm had a significantly higher mean change (difference Control-RAL; 95%CI) in haemoglobin (-2.9; -5.7, -1.1), total lymphocytes (-0.2; -0.3, -0.0), total cholesterol (-0.5; -0.8, -0.3), HDL cholesterol (-0.1; -0.1, -0.0) and LDL cholesterol (-0.3; -0.5, -0.2).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">At 96 weeks, both RAL and Control maintained efficacy greater than 75% and continued to demonstrate similar safety profiles. These results support the use of a combination LPV/r and RAL regimen as an option following failure of 1st line NNRTI + 2N(t)RTIs.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT00931463.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Janaki</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumarasamy</LastName><ForeName>Nagalingeswaran</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Y. R. Gaitonde Centre for AIDS Research and Education, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Cecilia L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Losso</LastName><ForeName>Marcello H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Hospital JM Ramos Mejia, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nwizu</LastName><ForeName>Chidi A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, University of Maryland School of Medicine, Baltimore, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohapi</LastName><ForeName>Lerato</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of the Witwatersrand and Baragwanath Hospital, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerr</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>UNSW Australia, The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sohn</LastName><ForeName>Annette H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>TREAT Asia, amfAR, The Foundation for AIDS Research, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teppler</LastName><ForeName>Hedy</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Merck Research Laboratories, Merck Sharp & Dohme, Whitehouse Station, New Jersey, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renjifo</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Global Medical Affairs Virology, Abbvie, North Chicago, Illinois, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Service des Maladies Infectieuses, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emery</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>The Kirby Institute, UNSW Australia, Sydney, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00931463</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019428">HIV Integrase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017320">HIV Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>43Y000U234</RegistryNumber><NameOfSubstance UI="D000068898">Raltegravir Potassium</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013;8(6):e66223</RefSource><PMID Version="1">23776637</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2013 Jun 15;381(9883):2091-9</RefSource><PMID Version="1">23769235</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934</RefSource><PMID Version="1">24239923</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Jul 17;371(3):234-47</RefSource><PMID Version="1">25014688</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013;8(8):e73639</RefSource><PMID Version="1">23951362</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Care. 2000 Jun;12(3):255-66</RefSource><PMID Version="1">10928201</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2001 Jul 11;286(2):180-7</RefSource><PMID Version="1">11448281</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Ther. 2004 Jan;26(1):92-7</RefSource><PMID Version="1">14996521</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 1999 Mar 16;130(6):461-70</RefSource><PMID Version="1">10075613</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2005 Nov 15;112(20):3066-72</RefSource><PMID Version="1">16275870</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2008 Jan 1;197(1):102-8</RefSource><PMID Version="1">18171292</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cochrane Database Syst Rev. 2010;(6):CD006517</RefSource><PMID Version="1">20556768</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>HIV Clin Trials. 2010 Jul-Aug;11(4):205-19</RefSource><PMID Version="1">20974576</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):73-7</RefSource><PMID Version="1">22743596</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2013 Jun;56(11):1637-45</RefSource><PMID Version="1">23362296</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Hum Retroviruses. 2013 Feb;29(2):256-65</RefSource><PMID Version="1">22730929</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2012;17(6):1011-20</RefSource><PMID Version="1">22910324</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>PLoS One. 2015;10(10):e0140623</RefSource><PMID Version="1">26451848</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019428" MajorTopicYN="N">HIV Integrase Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017320" MajorTopicYN="N">HIV Protease Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068898" MajorTopicYN="N">Raltegravir Potassium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063127" MajorTopicYN="N">Secondary Care</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4344344</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25723472</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0118228</ArticleId><ArticleId IdType="pii">PONE-D-14-16209</ArticleId><ArticleId IdType="pmc">PMC4344344</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F98 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002F98 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25723472
|texte= Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25723472" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |